19 June 2013
Keywords: first, data, bayer, oral, raf, kinase, inhibitor
Article | 27 March 2001
Onyx Pharmaceuticals and Bayer have reported Phase I clinical resultswith BAY-43-9006, claimed to be the first orally-active Raf kinase
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 March 2001
26 March 2001
4 April 2001
© 2013 thepharmaletter.com